Evolus, Inc. (NASDAQ:EOLS) has made a 58.52% comeback from a 12-month low price of $6.75. It was seen -26.96% lower, changing the price to $10.7, when the closing bell rang on 05/16/2018. At recent session, the prices were hovering between $9.55 and $12.2497. This company shares are 110.28% off its target price of $22.5 and the current market capitalization stands at $197.84M. The recent change has given its price a 9.12% lead over SMA 50 and -38.86% deficit over its 52-week high. The stock witnessed 13.23% gains, -6.96% declines and 0% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EOLS’s volatility during a week at 22.71% and during a month it has been found around 13.12%.Evolus, Inc. (EOLS) Top Holders
Institutional investors currently hold around $65 million or 4.7% in EOLS stock. Look at its top three institutional owners. Wellington Management Group Llp owns $34.22 million in Evolus, Inc., which represents roughly 17.3% of the company’s market cap and approximately 52.64% of the institutional ownership. Similar statistics are true for the second largest owner, Schroder Investment Management Group, which owns 500,000 shares of the stock are valued at $7.33 million. The third largest holder is Cormorant Asset Management, Lp, which currently holds $5.02 million worth of this stock and that ownership represents nearly 2.54% of its market capitalization.
At the end of 03/31/2018 reporting period, 40 institutional holders increased their position in Evolus, Inc. (NASDAQ:EOLS) by some 4,443,536 shares.
U.S. health regulators on Wednesday declined to approve Evolus Inc’s rival product to Allergan Plc’s Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines sending its shares down as much as 35 percent.
The company pushed its estimate for the launch of the drug, DWP-450, to the spring of next year. “What we’re going to work with from now to the launch date is how we create a value proposition around the product,” Chief Executive Officer David Moatazedi told Reuters, adding he viewed DWP-450 as the “first true alternative to Botox cosmetic.”
The deficiencies that were communicated by the U.S. Food and Drug Administration in a so-called complete response letter were “manageable”, according to CEO Moatazedi, who joined the company earlier this month after serving as U.S. head of Allergan’s medical aesthetics business.
The issues cited by the FDA, were isolated to items related to chemistry, manufacturing, and controls processes, and none related to clinical or non-clinical matters, the company said.
Analysts believe Evolus would be able to meet its new timeline for the launch of the product but said a shorter delay may have been anticipated.
Evolus’s DWP-450, a Botox-like treatment, is a botulinum toxin injection to treat glabellar lines or frown lines in adult patients.
Allergan’s Botox is the market leader for the treatment of wrinkles and frown lines, but threat of looming competition for the blockbuster treatment has put some pressure on the drugmaker. In February, Revance Therapeutics teamed up with Mylan NV to develop a biosimilar of Botox.
Mizuho analyst Irina Koffler said the delay in approval for DWP-450 would allow Allergan more time to prepare “competitive responses”.Evolus, Inc. (EOLS) Analyst Guide
Several analysts have released their opinion on Evolus, Inc. (NASDAQ:EOLS), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.